Metabolism of a highly selective gelatinase inhibitor generates active metabolite

Chemical Biology and Drug Design

Volumn 70, Issue 5, 2007, Pages 371-382

  Lee, Mijoon ^a   Villegas Estrada, Adriel ^a   Celenza, Giuseppe ^a   Boggess, Bill ^a   Toth, Marta ^a   Kreitinger, Gloria ^a   Forbes, Christopher ^a   Fridman, Rafael ^b   Mobashery, Shahriar ^a   Chang, Mayland ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Active metabolite; Metabolism; Selective matrix metalloproteinase inhibitor

Indexed keywords

1 CHLORO 3 (4 PHENYLSULFANYL)PROPAN 2 OL; 1 CHLORO 3 [4 [2,3,4,5,6 D5]PHENOXYPHENYLSULFANYL]PROPAN 2 OL; 2 [(4 PHENOXYPHENYLSULFONYL)METHYL]THIIRANE S OXIDE; 2 [4 [2,3,4,5,6 D5]PHENOXYPHENYLSULFONYLMETHYL]THIIRANE; 2 [4 PHENOXY[2,3,5,6 D4]PHENYLSULFONYLMETHYL]THIIRANE; 4 (4 THIIRANYLMETHANESULFONYLPHENOXY)PHENOL; 4 (BROMOPHENYL D4)PHENYL ETHER; 4 PHENOXYBENZENESULFONYL CHLORIDE; 4 PHENOXYPHENYLSULFONYL METHYLTHIIRANE; [[(4 PHENOXYPHENYL)SULFONYL]METHYL D2]THIIRANE D3; DRUG METABOLITE; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; SODIUM 4 PHENOXYBENZENESULFINATE; SODIUM 4 PHENOXYBENZENESULFONATE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT;

DRUG DESIGN; GELATINASES; HUMANS; KINETICS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MODELS, MOLECULAR; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

ANIMALIA;

EID: 35348950561     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00577.x     Document Type: Article

References (27)

1. Lee M., Fridman R., Mobashery S. (2004) Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 33: 401 409.
2. Massova I., Kotra L.P., Fridman R., Mobashery S. (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12: 1075 1095.
3. Nagase H., Meng Q., Malinovskii V., Huang W., Chung L., Bode W., Maskos K., Brew K. (1999) Engineering of Selective TIMPs. Inhibition of Matrix Metalloproteinases: Therapeutic Applications. New York Academy of Sciences: NY p. 1 11.
4. Stamenkovic I. (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200: 448 464.
5. Sternlicht M.D., Coussens L.M., Vu T.H., Werb Z. (2001) Biology and Regulation of the Matrix Metalloproteinases. Matrix Metalloproteinase Inhibitors in Cancer Therapy. Human Press: NJ p. 1 37.
6. Bergers G., Benjamin L.E. (2003) Angiogenesis: tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401 410.
7. Kerbel R., Folkman J. (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727 739.
8. Steeg P.S. (2003) Angiogenesis inhibitors: motivators of metastasis? Nat Med 9: 822 823.
9. Van't Veer Laura J., Weigelt B. (2003) Road map to metastasis. Nat Med 9: 999 1000.
10. Brown S., Bernardo M.M., Li Z.H., Kotra L.P., Tanaka Y., Fridman R., Mobashery S. (2000) Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 122: 6799 6800.
11. Bonfil R.D., Dong Z., Trindade Filho J.C., Sabbota A., Osenkowski P., Nabha S., Yamamoto H., Chinni Sreenivasa R., Zhao H., Mobashery S., Vessella Robert L., Fridman R., Cher Michael L. (2007) Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 170: 2100 2111.
12. Bonfil R.D., Sabbota A., Nabha S., Bernardo M.M., Dong Z., Meng H., Yamamoto H., Chinni S.R., Lim I.T., Chang M., Filetti L.C., Mobashery S., Cher M.L., Fridman R. (2006) Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer 118: 2721 2726.
13. Kruger A., Arlt M.J.E., Gerg M., Kopitz C., Bernardo M.M., Chang M., Mobashery S., Fridman R. (2005) Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 65: 3523 3526.
14. Gu Z.Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A.Y., Lipton S.A. (2005) A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25: 6401 6408.
15. Olson M.W., Gervasi D.C., Mobashery S., Fridman R. (1997) Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 272: 29975 29983.
16. Ikejiri M., Bernardo M.M., Bonfil R.D., Toth M., Chang M.L., Fridman R., Mobashery S. (2005) Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 280: 33992 34002.
17. Olson M.W., Bernardo M.M., Pietila M., Gervasi D.C., Toth M., Kotra L.P., Massova I., Mobashery S., Fridman R. (2000) Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem 275: 2661 2668.
18. Toth M., Gervasi D.C., Fridman R. (1997) Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human mcf10a breast epithelial cells. Cancer Res 57: 3159 3167.
19. Lee M., Bernardo M.M., Meroueh S.O., Brown S., Fridman R., Mobashery S. (2005) Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett 7: 4463 4465.
20. Lim I.T., Brown S., Mobashery S. (2004) A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent. J Org Chem 69: 3572 3573.
21. Chan D.M.T., Monaco K.L., Wang R.P., Winters M.P. (1998) New N- and O-arylations with phenylboronic acids and cupric acetate. Tetrahedron Lett 39: 2933 2936.
22. Evans D.A., Katz J.L., West T.R. (1998) Synthesis of diaryl ethers through the copper-promoted arylation of phenols with arylboronic acids. An expedient synthesis of thyroxine. Tetrahedron Lett 39: 2937 2940.
23. Ma D.W., Cai Q. (2003) N,N-Dimethyl glycine-promoted ullmann coupling reaction of phenols and aryl halides. Org Lett 5: 3799 3802.
24. Beynon J.H., Lester G.R., Williams A.E. (1959) Some specific molecular rearrangements in the mass spectra of organic compounds. J Phys Chem 63: 1861 1868.
25. Taniwaki K., Fukamachi H., Komori K., Ohtake Y., Nonaka T., Sakamoto T., Shiomi T., Okada Y., Itoh T., Itohara S., Seiki M., Yana I. (2007) Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res 67: 4311 4319.
26. Hotary Kevin B., Allen Edward D., Brooks Peter C., Datta Nabanita S., Long Michael W., Weiss Stephen J. (2003) Membrane type i matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114: 33 45.
27. Toth M., Bernardo M.M., Gervasi D.C., Soloway P.D., Wang Z.P., Bigg H.F., Overall C.M., DeClerck Y.A., Tschesche H., Cher M.L., Brown S., Mobashery S., Fridman R. (2000) Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem 275: 41415 41423.